Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Dianne Madelyn Finkelstein, Ph.D.

Co-Author

This page shows the publications co-authored by Dianne Finkelstein and Paul Goss.
Connection Strength

3.032
  1. A phase III trial of adjuvant neratinib (NER) after trastuzumab (TRAS) in women with early-stage HER2+ breast cancer (BC). J Clin Oncol. 2011 May 20; 29(15_suppl):TPS137.
    View in: PubMed
    Score: 0.469
  2. Real world patterns of care in HER2-overexpressing breast cancer: Results of a survey of TEACH clinical trial investigators in 2011. Breast. 2017 Feb; 31:197-201.
    View in: PubMed
    Score: 0.172
  3. Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. Eur J Cancer. 2016 Mar; 56:85-92.
    View in: PubMed
    Score: 0.162
  4. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. Breast Cancer Res. 2015 Apr 16; 17:56.
    View in: PubMed
    Score: 0.154
  5. Pregnancy-associated breast cancer in women from Shanghai: risk and prognosis. Breast Cancer Res Treat. 2015 Jan; 149(1):255-61.
    View in: PubMed
    Score: 0.150
  6. Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy. Br J Cancer. 2014 Nov 25; 111(11):2046-50.
    View in: PubMed
    Score: 0.148
  7. Access to care issues adversely affect breast cancer patients in Mexico: oncologists' perspective. BMC Cancer. 2014 Sep 09; 14:658.
    View in: PubMed
    Score: 0.147
  8. Breast cancer in China. Lancet Oncol. 2014 Jun; 15(7):e279-89.
    View in: PubMed
    Score: 0.145
  9. Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury. J Clin Oncol. 2014 Aug 01; 32(22):2296-303.
    View in: PubMed
    Score: 0.143
  10. Outcomes of breast cancer in Brazil related to health care coverage: a retrospective cohort study. Cancer Epidemiol Biomarkers Prev. 2014 Jan; 23(1):126-33.
    View in: PubMed
    Score: 0.139
  11. Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. J Natl Cancer Inst. 2013 Jul 17; 105(14):1036-42.
    View in: PubMed
    Score: 0.136
  12. Planning cancer control in Latin America and the Caribbean. Lancet Oncol. 2013 Apr; 14(5):391-436.
    View in: PubMed
    Score: 0.133
  13. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol. 2013 Jan; 14(1):88-96.
    View in: PubMed
    Score: 0.131
  14. Breast cancer in Mexico: a growing challenge to health and the health system. Lancet Oncol. 2012 Aug; 13(8):e335-43.
    View in: PubMed
    Score: 0.127
  15. Breast cancer in Brazil: present status and future goals. Lancet Oncol. 2012 Mar; 13(3):e95-e102.
    View in: PubMed
    Score: 0.124
  16. Prediction of late recurrences by breast cancer index in the NCIC CTG MA.17 cohort. J Clin Oncol. 2011 Sep 20; 29(27_suppl):2.
    View in: PubMed
    Score: 0.120
  17. A phase II clinical trial of drug withdrawal in women with progressive breast cancer while on aromatase inhibitor therapy. J Clin Oncol. 2011 May 20; 29(15_suppl):559.
    View in: PubMed
    Score: 0.117
  18. A randomized, double-blind, placebo-controlled multicenter phase III study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE). J Clin Oncol. 2011 May 20; 29(15_suppl):TPS152.
    View in: PubMed
    Score: 0.117
  19. Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis. Front Oncol. 2018; 8:156.
    View in: PubMed
    Score: 0.048
  20. Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer. Cancer Discov. 2018 03; 8(3):336-353.
    View in: PubMed
    Score: 0.046
  21. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2015 Jun 10; 33(17):1902-9.
    View in: PubMed
    Score: 0.038
  22. Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer. Eur J Cancer. 2015 Apr; 51(6):685-96.
    View in: PubMed
    Score: 0.038
  23. TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response. J Clin Oncol. 2011 May 20; 29(15_suppl):1025.
    View in: PubMed
    Score: 0.029
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.